4784-02-5

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Dihydroxy-6,7-dimethoxyquinoxaline is used as a pharmaceutical candidate for its potential antioxidant properties. Its ability to neutralize free radicals and protect cells from oxidative damage makes it a valuable compound for the development of drugs targeting various diseases and conditions associated with oxidative stress.
Used in Medicinal Chemistry Research:
2,3-Dihydroxy-6,7-dimethoxyquinoxaline is used as a research compound in medicinal chemistry to explore its potential applications in drug development. Its unique structure and properties provide a foundation for further investigation into its biological activities, mechanism of action, and potential therapeutic uses.

InChI:InChI=1/C10H10N2O4/c1-15-7-3-5-6(4-8(7)16-2)12-10(14)9(13)11-5/h3-4H,1-2H3,(H,11,13)(H,12,14)

Upstream product

• 144-62-7 oxalic acid 
• 27841-33-4 4,5-dimethoxybenzene-1,2-diamine 
• 3395-03-7 4,5-dimethoxy-1,2-dinitrobenzene 
• 6153-56-6 oxalic acid dihydrate 
• 91-16-7 1,2-dimethoxybenzene 

Downstream Products

• 1790-91-6 2,3-Dichloro-6,7-dimethoxyquinoxaline 

Relevant academic research and scientific papers

PHOSPHOGLYCERATE KINASE INHIBITORS

Disclosed are compounds of formula (I) or pharmaceutical acceptable salts thereof, wherein R1, R2, R3 and R4 are as defined in the description. Disclosed are also the methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as phosphoglycerate kinase.

Imidazoquinoxaline protein tyrosine kinase inhibitors

Novel imidazoquinoxalines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.

Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.

Acetoxylation of 6,7-dialkoxy-substituted 1,4-dihydroquinoxaline-2,3-diones (QXs) using fuming nitric acid in acetic acid: A facile synthesis of 5-acyloxy-6,7-dialkoxy QXs

Treatment of 6,7-dialkoxy-1,4-dihydroquinoxaline-2,3-diones 3 with fuming nitric acid in acetic acid at 25°C resulted in an acetoxylation reaction, giving 5-acetoxy-6,7-dialkoxy-1,4-dihydroquinoxaline-2,3-diones 4 in moderate yields. A mechanism involving ipso attack of nitronium ion as the first step is proposed.